{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hua X"],"funding":["the cultivation foundation for the junior teachers in Sun Yat-sen University","Natural Science Foundation of Guangdong Province","Sci-Tech Project Foundation of Guangzhou City"],"pagination":["637-645"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9377763"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(4)"],"pubmed_abstract":["<h4>Purpose</h4>There is no research evidence demonstrate which is the better partner strategy, endocrine therapy or chemotherapy, to combine with anti-HER2 therapy as the first-line management of hormone receptor (HR)-positive (HR+) and HER2-positive (HER2+) metastatic breast cancer (MBC). We wished to ascertain if trastuzumab plus endocrine therapy is noninferior to trastuzumab plus chemotherapy.<h4>Patients and methods</h4>We conducted an open-label, noninferiority, phase III, randomized, controlled trial (NCT01950182) at nine hospitals in China. Participants, stratified by previous adjuvant endocrine therapy and disease status (recurrent disease vs. de novo metastasis), were assigned randomly (1:1) to receive trastuzumab plus endocrine therapy (per investigator's choice of oestrogen-re"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)."],"pmcid":["PMC9377763"],"funding_grant_id":["202002020033","20ykpy164","2019A151011781"],"pubmed_authors":["Hua X","Huang JJ","Zhang LH","Guo Y","Xue C","Shi YX","Huang H","Bi XW","Lin Y","Xu F","Jiang KK","Yuan ZY","Xia W","Hong RX","Liu XM","Zhang AQ","Zhao JL","Zhang YQ","An X","Wang SS","Wu ZY","Zhong YY"],"additional_accession":[]},"is_claimable":false,"name":"Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002).","description":"<h4>Purpose</h4>There is no research evidence demonstrate which is the better partner strategy, endocrine therapy or chemotherapy, to combine with anti-HER2 therapy as the first-line management of hormone receptor (HR)-positive (HR+) and HER2-positive (HER2+) metastatic breast cancer (MBC). We wished to ascertain if trastuzumab plus endocrine therapy is noninferior to trastuzumab plus chemotherapy.<h4>Patients and methods</h4>We conducted an open-label, noninferiority, phase III, randomized, controlled trial (NCT01950182) at nine hospitals in China. Participants, stratified by previous adjuvant endocrine therapy and disease status (recurrent disease vs. de novo metastasis), were assigned randomly (1:1) to receive trastuzumab plus endocrine therapy (per investigator's choice of oestrogen-re","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-07-14T21:08:44.924Z","creation":"2026-06-24T03:09:55.724Z"},"accession":"S-EPMC9377763","cross_references":{"pubmed":["34810217"],"doi":["10.1158/1078-0432.CCR-21-3435"]}}